IL228793D0 - Il-12/p40 binding proteins - Google Patents

Il-12/p40 binding proteins

Info

Publication number
IL228793D0
IL228793D0 IL228793A IL22879313A IL228793D0 IL 228793 D0 IL228793 D0 IL 228793D0 IL 228793 A IL228793 A IL 228793A IL 22879313 A IL22879313 A IL 22879313A IL 228793 D0 IL228793 D0 IL 228793D0
Authority
IL
Israel
Prior art keywords
hil
antibodies
il
invention
activity
Prior art date
Application number
IL228793A
Other languages
Hebrew (he)
Original Assignee
Abbvie Inc
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US69567905P priority Critical
Priority to PCT/US2006/025584 priority patent/WO2007005608A2/en
Application filed by Abbvie Inc, Abbott Lab filed Critical Abbvie Inc
Publication of IL228793D0 publication Critical patent/IL228793D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.
IL228793A 2005-06-30 2013-10-08 Il-12/p40 binding proteins IL228793D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US69567905P true 2005-06-30 2005-06-30
PCT/US2006/025584 WO2007005608A2 (en) 2005-06-30 2006-06-29 Il-12/p40 binding proteins

Publications (1)

Publication Number Publication Date
IL228793D0 true IL228793D0 (en) 2013-12-31

Family

ID=37605037

Family Applications (3)

Application Number Title Priority Date Filing Date
IL187691A IL187691A (en) 2005-06-30 2007-11-27 Binding protein capable of binding a p40 subunit of il-12 and il-23, method for preparing the same and a pharmaceutical composition for reducing or inhibiting il-12 activity
IL21680311A IL216803D0 (en) 2005-06-30 2011-12-06 A binding protein capable of binding a p40 subunit of il-12 and il-23, a method for preparing the same and a pharmaceutical composition for reducing or inhibiting il-12 activity
IL228793A IL228793D0 (en) 2005-06-30 2013-10-08 Il-12/p40 binding proteins

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IL187691A IL187691A (en) 2005-06-30 2007-11-27 Binding protein capable of binding a p40 subunit of il-12 and il-23, method for preparing the same and a pharmaceutical composition for reducing or inhibiting il-12 activity
IL21680311A IL216803D0 (en) 2005-06-30 2011-12-06 A binding protein capable of binding a p40 subunit of il-12 and il-23, a method for preparing the same and a pharmaceutical composition for reducing or inhibiting il-12 activity

Country Status (18)

Country Link
US (3) US7700739B2 (en)
EP (1) EP1907421A4 (en)
JP (2) JP5396080B2 (en)
KR (2) KR20080028895A (en)
CN (11) CN103172737A (en)
AU (1) AU2006265932B2 (en)
BR (1) BRPI0611714A2 (en)
CA (2) CA2848662A1 (en)
CR (10) CR9599A (en)
IL (3) IL187691A (en)
MX (1) MX2007016401A (en)
NO (1) NO20080557L (en)
NZ (1) NZ596992A (en)
RU (1) RU2461571C2 (en)
TW (2) TW201444869A (en)
UA (1) UA96922C2 (en)
WO (1) WO2007005608A2 (en)
ZA (1) ZA201201216B (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2848662A1 (en) * 2005-06-30 2007-01-11 Abbvie Inc. Il-12/p40 binding proteins
EP1933869B1 (en) 2005-09-01 2009-10-14 Schering Corporation Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
CN102846585A (en) 2006-03-28 2013-01-02 杰佛林制药公司 Formulations of low dose diclofenac and beta-cyclodextrin
US8168760B2 (en) 2007-03-29 2012-05-01 Abbott Laboratories Crystalline anti-human IL-12 antibodies
AU2008328781A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
CN101969929B (en) 2008-01-15 2014-07-30 Abbvie德国有限责任两合公司 Powdered protein compositions and methods of making same
TWI501776B (en) 2008-08-14 2015-10-01 Cephalon Australia Pty Ltd Anti-il-12/il-23 antibodies
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
RU2011140335A (en) 2009-03-05 2013-04-10 Эбботт Лэборетриз BINDING IL-17 Proteins
CN101935687B (en) 2009-06-29 2012-11-07 中国科学院上海生命科学研究院 Application of IL-12p40 siRNA to promoting liver regeneration
AR078161A1 (en) * 2009-09-11 2011-10-19 Hoffmann La Roche highly concentrated anti-CD20 antibody of pharmaceutical formulations. Use of the formulation. treatment method.
JO3244B1 (en) 2009-10-26 2018-03-08 Amgen Inc Human il-23 antigen binding proteins
CA2783715A1 (en) * 2009-12-29 2011-07-07 F. Hoffmann-La Roche Ag Novel antibody formulation
CA2791962A1 (en) * 2010-03-01 2011-09-09 Alexion Pharmaceuticals, Inc. Methods and compositions for treating degos' disease
UA107490C2 (en) * 2010-04-07 2015-01-12 Еббві Інк. TNF-a-BINDING PROTEINS
BR122014011544A2 (en) 2010-05-14 2019-08-13 Abbvie Inc il-1 binding proteins
ES2395801B1 (en) * 2011-06-23 2014-06-06 María Carmen PARDINA PALLEJÀ "pentoxifilina by transvaginal route for the treatment of infertility"
MX354988B (en) 2011-10-25 2018-03-28 Prothena Biosciences Ltd Antibody formulations and methods.
WO2013177115A2 (en) * 2012-05-21 2013-11-28 Abbvie Inc. Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
MX364535B (en) 2012-10-03 2019-04-29 Philogen Spa Antigens associated with inflammatory bowel disease.
CN105164535B (en) * 2013-02-14 2018-04-10 法龙药品公司 Methods determining acute respiratory distress syndrome (ards) related biomarkers, the development of monitoring and treatment of patients ards
KR20150122761A (en) * 2013-02-26 2015-11-02 로슈 글리카트 아게 Bispecific t cell activating antigen binding molecules
WO2015010108A1 (en) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
CA2920835A1 (en) 2013-08-20 2015-02-26 Anutra Medical, Inc. Syringe fill system and method
KR20160113710A (en) * 2014-01-30 2016-09-30 코히러스 바이오사이언시즈, 인코포레이티드 Perfusion media
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CN105353135A (en) * 2015-11-23 2016-02-24 中国人民解放军第三军医大学第一附属医院 Use of Alzheimer's disease marker
WO2018005682A2 (en) * 2016-06-29 2018-01-04 Checkpoint Therapeutics, Inc. Pd-l1-specific antibodies and methods of using the same
CN110121509A (en) 2016-10-26 2019-08-13 西达-赛奈医疗中心 Neutralize anti-TL1A monoclonal antibody

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3378250D1 (en) * 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) * 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
EP0590689B2 (en) * 1985-03-30 2006-08-16 KAUFFMAN, Stuart A. Method for obtaining DNA, RNA, peptides, polypeptides or proteins by means of a DNA-recombinant technique
US6492107B1 (en) * 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (en) * 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド Denaturation antibody, or improvements relating modified antibody
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4880078A (en) * 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA1340288C (en) 1988-09-02 1998-12-29 Robert Charles Ladner Generation and selection of novel binding proteins
EP1279731B1 (en) 1991-03-01 2007-05-30 Dyax Corporation Process for the development of binding mini-proteins
ES2052027T5 (en) 1988-11-11 2005-04-16 Medical Research Council Cloning sequence immunoglobulin variable domain.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
AU652539B2 (en) 1989-05-16 1994-09-01 Medical Research Council Co-expression of heteromeric receptors
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
WO1991006287A1 (en) * 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) * 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
DE69120146T2 (en) 1990-01-12 1996-12-12 Cell Genesys Inc Generating xenogeneic antibody
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0605522B1 (en) 1991-09-23 1999-06-23 Cambridge Antibody Technology Limited Methods for the production of humanized antibodies
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH06508511A (en) 1990-07-10 1994-09-29 Medical Res Council
AT174598T (en) 1990-08-24 1999-01-15 Ixsys Inc A process for the preparation of oligonucleotides having random codons
US5698426A (en) * 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (en) * 1990-12-03 1998-08-20 Genentech Inc A method for enrichment of protein variants with altered binding properties
DE69131017T2 (en) 1990-12-20 1999-07-15 Ixsys Inc Optimization of binding proteins
PT100379B (en) 1991-04-10 1999-01-29 Scripps Research Inst Libraries of heterodymeric receptors using fagomideos
JPH06507404A (en) 1991-05-01 1994-08-25
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co., Inc. A method for reducing the immunogenicity of antibody variable domains
AU2238292A (en) 1991-06-14 1993-01-12 Xoma Corporation Microbially-produced antibody fragments and their conjugates
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for antibody screening
ES2227512T3 (en) 1991-12-02 2005-04-01 Cambridge Antibody Technology Limited Production of antibodies against self-antigens from repertoires of antibody segments fixed in a phage.
ES2136092T3 (en) * 1991-09-23 1999-11-16 Medical Res Council Procedures for the production of humanized antibodies.
CA2103887C (en) * 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6019968A (en) * 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5934272A (en) * 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
WO1994018219A1 (en) 1993-02-02 1994-08-18 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5565352A (en) * 1993-11-24 1996-10-15 Arch Development Corporation Deubiquitinating enzyme: compositions and methods
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
US5516637A (en) * 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6091001A (en) * 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) * 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
AU705616B2 (en) * 1995-04-21 1999-05-27 Cell Genesys, Inc. Generation of large genomic DNA deletions
US5916597A (en) * 1995-08-31 1999-06-29 Alkermes Controlled Therapeutics, Inc. Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent
JP2978435B2 (en) * 1996-01-24 1999-11-15 チッソ株式会社 Method for producing acryloxypropyl silane
ES2395214T3 (en) * 1996-03-04 2013-02-11 The Penn State Research Foundation Materials and methods to increase cellular internalization
US5714352A (en) * 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6699658B1 (en) * 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US5916771A (en) * 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5989463A (en) * 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
TR200002145T2 (en) * 1998-01-23 2000-11-21 F.Hoffmann-La Roche Ag Human IL-12 Antibodies
US5989263A (en) * 1998-03-11 1999-11-23 Arteria Medical Science L.L.C. Hydraulically actuated dilatation mechanism for vessel dilatation and vascular prosthesis delivery and methods of use
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
TR200102715T2 (en) * 1999-03-25 2002-09-23 Knoll Gmbh Binds human IL-12 human antibodies and methods for producing them.
ES2568899T3 (en) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedure to control the activity of an immunofunctional molecule
KR100823764B1 (en) * 2000-06-22 2008-04-21 제넨테크, 인크. Agonist anti-trk-C monoclonal antibodies
US7449308B2 (en) * 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
EP1522590B1 (en) * 2000-06-28 2009-08-26 Glycofi, Inc. Methods for producing modified glycoproteins
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
KR20030074693A (en) 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 Crystals of whole antibodies and fragments thereof and methods for making and using them
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
EP1385544B1 (en) 2001-04-30 2008-09-24 Eli Lilly And Company Humanized antibodies
AU2002314825A1 (en) * 2001-05-30 2002-12-09 Centocor, Inc. Anti-p40 immunoglobulin derived proteins, compositions, methods and uses
US20040192898A1 (en) 2001-08-17 2004-09-30 Jia Audrey Yunhua Anti-abeta antibodies
AT346866T (en) 2001-09-14 2006-12-15 Affimed Therapeutics Ag Multimeric, single, tandem Fv antibody
DE60232672D1 (en) * 2001-10-01 2009-07-30 Dyax Corp Multi-chain eukaryotic display-vectors and their uses
EP1478371A4 (en) * 2001-10-12 2007-11-07 Univ Iowa Res Found Methods and products for enhancing immune responses using imidazoquinoline compounds
BR0213761A (en) 2001-10-25 2005-04-12 Genentech Inc Compositions, pharmaceutical preparations, industrial article, method of treatment of mammals, host cell, method for producing a glycoprotein and use of the composition
KR101053412B1 (en) * 2002-10-30 2011-08-01 제넨테크, 인크. Suppression of IL-173 Production
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
AU2004218354B2 (en) 2003-03-05 2009-10-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
AU2004239288B2 (en) * 2003-05-09 2010-01-28 Centocor, Inc. IL-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
WO2004101511A2 (en) 2003-05-09 2004-11-25 Protein Design Labs, Inc Anti-ip-10 antibodies and methods of using thereof for the treatment of inflamatory bowel diseases
WO2004106381A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
CA2537055A1 (en) * 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
CN1950496B (en) 2004-04-15 2015-02-04 格利科菲公司 Production of galactosylated glycoproteins in lower eukaryotes
NZ583153A (en) * 2004-12-21 2011-06-30 Centocor Ortho Biotech Inc Anti-IL-12 antibodies, epitopes, compositions, methods and uses
CA2848662A1 (en) * 2005-06-30 2007-01-11 Abbvie Inc. Il-12/p40 binding proteins

Also Published As

Publication number Publication date
BRPI0611714A2 (en) 2009-01-13
CN103172739A (en) 2013-06-26
CN103172738A (en) 2013-06-26
KR20080028895A (en) 2008-04-02
CR20130150A (en) 2013-05-23
CN101379085B (en) 2013-03-27
TW200745160A (en) 2007-12-16
IL216803D0 (en) 2012-01-31
CR20130155A (en) 2013-05-23
JP5396080B2 (en) 2014-01-22
CN103146708A (en) 2013-06-12
AU2006265932A1 (en) 2007-01-11
KR20130080058A (en) 2013-07-11
CR20130154A (en) 2013-05-23
CN103145837A (en) 2013-06-12
US20100047245A1 (en) 2010-02-25
CR20130153A (en) 2013-05-23
CN103145839A (en) 2013-06-12
NO20080557L (en) 2008-01-30
UA96922C2 (en) 2011-12-26
EP1907421A4 (en) 2012-03-28
NZ596992A (en) 2013-07-26
IL187691D0 (en) 2008-08-07
JP2009500018A (en) 2009-01-08
WO2007005608A3 (en) 2008-10-09
CA2848662A1 (en) 2007-01-11
CR20130151A (en) 2013-05-23
MX2007016401A (en) 2008-02-20
CR9599A (en) 2009-06-05
US20100196315A1 (en) 2010-08-05
CR20130152A (en) 2013-05-23
CN103172737A (en) 2013-06-26
CN103145840A (en) 2013-06-12
CR20130149A (en) 2013-05-23
CN101379085A (en) 2009-03-04
CN103145841A (en) 2013-06-12
CA2612239A1 (en) 2007-01-11
IL187691A (en) 2013-10-31
US20140178332A1 (en) 2014-06-26
WO2007005608A2 (en) 2007-01-11
US8629257B2 (en) 2014-01-14
TW201444869A (en) 2014-12-01
US7700739B2 (en) 2010-04-20
RU2461571C2 (en) 2012-09-20
CN103145838A (en) 2013-06-12
EP1907421A2 (en) 2008-04-09
JP2013177405A (en) 2013-09-09
ZA201201216B (en) 2012-11-28
CR20130157A (en) 2013-05-23
RU2008103312A (en) 2009-08-10
CN103145842A (en) 2013-06-12
AU2006265932B2 (en) 2012-10-25
CR20130156A (en) 2013-05-23

Similar Documents

Publication Publication Date Title
TWI350290B (en) Human antibodies specific for interleukin 15 (il-15)
CA2389943A1 (en) Human antibodies that bind human tnf.alpha.
NZ547157A (en) Interferon Alpha Antibodies and their uses
WO2005118635A3 (en) Anti-cd3 antibodies and methods of use thereof
IL172869A (en) Antibody that binds for human il-13 and rhesus or cynomolgus il-13, method for its production and pharmaceutical composition comprising it
WO2004106380A3 (en) Human-anti-human cd3 binding molecules
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
MXPA04003345A (en) Angiopoietin-2 specific binding agents.
RU2013133714A (en) Monoclonal human antibodies to programmable death protein 1 (pd-1) and cancer treatment methods using anti-pd-1 antibodies independently or in combination with other importance
WO2011066369A3 (en) Antagonists of il-6 to raise albumin and/or lower crp
CY1113097T1 (en) Antibodies of il-17
HK1103746A1 (en) Antibodies to erythropoietin receptor and uses thereof
EP1814586A4 (en) Anti-properdin antibodies, and methods for making and using same
NZ569718A (en) Novel anti-IGF-IR antibodies and uses thereof
EP2404616A3 (en) Binding proteins specific for insulin-like growth factors and uses thereof
WO2006050491A3 (en) Methods for antibody engineering
WO2006028936A3 (en) Heteromultimeric molecules
TW200635608A (en) Aβ antibodies for use in improving cognition
UA99701C2 (en) Human monoclonal antibody that specifically binds to programmed death ligand 1 (pd-l1)
NO20026239D0 (en) Antibodies with dual specificity and to methods for making and using
EP1753880A4 (en) Methods for treating cancer using anti-wnt2 monoclonal antibodies and sirna
TW200934510A (en) Antibodies to GDF8 as uses thereof
WO2008017963A4 (en) Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
WO2006111353A3 (en) Antibody neutralizers of human granulocyte macrophage colony stimulating factor
EA200600905A1 (en) ANTIGENSBELTING MOLECULES WITH HIGH AFFINITY TO BINDING WITH Fc-RECEPTOR AND EFFECTOR